AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 209.24

Change

0.00 (0.00)%

Market Cap

USD 118.82B

Volume

1.35M

Avg Analyst Target

USD 246.00 (+17.57%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

N/A

USD192.19B 43.04 22.53
SNY Sanofi

N/A

USD125.32B 18.60 12.19
GILD Gilead Sciences Inc

N/A

USD84.31B 16.46 11.18
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

N/A

USD38.90B 21.18 14.79
HZNP Horizon Therapeutics Public Li..

N/A

USD26.31B 53.20 36.65
GRFS Grifols S.A

N/A

USD13.67B 24.35 14.97
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16
CRXT Clarus Therapeutics Holdings I..

N/A

USD0.09B N/A N/A
CRXTW Clarus Therapeutics Holdings I..

N/A

N/A N/A N/A

ETFs Containing AMGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.57B
EXI3:XETRA iShares Dow Jones Industr.. 0.00 % 0.51 %

N/A

USD6,289.39B
EKUS:PA BNP Paribas Easy - MSCI U.. 0.00 % 0.00 %

N/A

USD0.39B
3SUR:F iShares IV Public Limited.. 0.00 % 0.23 %

N/A

N/A
BBCK:F Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
EMWE:F BNP Paribas Easy - MSCI W.. 0.00 % 0.00 %

N/A

N/A
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.51 %

N/A

USD6,289.39B
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD0.39B
SXRU:F iShares VII Public Limite.. 0.00 % 0.33 %

N/A

USD0.87B
UIMP:F UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

N/A

USD2.07B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.40B
BBCK:XETRA Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
MJMT:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD0.46B
VMVL:LSE Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
SXRU:XETRA iShares VII Public Limite.. 0.00 % 0.33 %

N/A

USD0.88B
UEFY:XETRA UBS ETF SICAV - SBI Forei.. 0.00 % 0.20 %

N/A

USD0.19B
UET1:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

N/A

USD0.14B
UIMP:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

N/A

USD2.07B
VMVL:XETRA Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
ZPAY:CA BMO Premium Yield ETF 0.00 % 0.73 %

N/A

N/A
ESNG Direxion MSCI USA ESG - L.. 0.00 % 0.40 %

N/A

N/A
TACE Trend Aggregation Conserv.. 0.00 % 1.87 %

N/A

N/A
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
ZPAY-F:CA BMO Premium Yield ETF 0.00 % 0.00 %

N/A

N/A
ZPAY-U:CA BMO Premium Yield ETF 0.00 % 0.72 %

N/A

N/A
BUYB:PA Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
SBUY:LSE Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.27B
UDOW ProShares Trust - ProShar.. 0.00 % 0.95 %

N/A

USD1.06B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD9.12M
BLV Vanguard Long-Term Bond I.. 0.00 % 0.05 %

N/A

USD11.04B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

N/A

USD0.49B
DIA SPDR Dow Jones Industrial.. 0.00 % 0.16 %

N/A

USD30.46B
DJD Invesco Dow Jones Industr.. 0.00 % 0.07 %

N/A

USD0.17B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

N/A

USD10.94B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

N/A

USD0.30B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD0.37B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
VVO:CA Vanguard Global Minimum V.. 0.00 % 0.36 %

N/A

USD0.04B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.69B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZDJ:CA BMO Dow Jones Industrial .. 0.00 % 0.26 %

N/A

USD0.32B
ZWA:CA BMO Covered Call Dow Jone.. 0.00 % 0.72 %

N/A

USD0.22B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.72 %

N/A

USD0.04B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

N/A

USD0.51B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.74 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.49B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

N/A

USD0.49B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.04B
CIND:LSE iShares VII Public Limite.. 0.00 % 0.33 %

N/A

USD0.87B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.99% 29% F 29% F
Dividend Return 2.30% 20% F 57% F
Total Return -6.70% 29% F 31% F
Trailing 12 Months  
Capital Gain -7.89% 29% F 21% F
Dividend Return 3.03% 40% F 54% F
Total Return -4.86% 29% F 23% F
Trailing 5 Years  
Capital Gain 31.80% 57% F 46% F
Dividend Return 17.86% 60% D- 72% C-
Total Return 49.66% 57% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 9.99% 71% C- 51% F
Dividend Return 2.98% 60% D- 72% C-
Total Return 12.97% 71% C- 55% F
Risk Return Profile  
Volatility (Standard Deviation) 12.82% 57% F 86% B
Risk Adjusted Return 101.15% 71% C- 94% A
Market Capitalization 118.82B 75% C 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.22 57% F 42% F
Price/Book Ratio 13.99 14% F 9% F
Price / Cash Flow Ratio 11.32 63% D 34% F
EV/EBITDA 12.56 71% C- 56% F
Management Effectiveness  
Return on Equity 60.79% 100% A+ 98% A+
Return on Invested Capital 20.18% 100% A+ 89% B+
Return on Assets 9.13% 86% B 91% A-
Debt to Equity Ratio 349.61% 14% F 6% F
Technical Ratios  
Short Ratio 4.34 25% F 35% F
Short Percent 1.96% 25% F 61% D-
Beta 0.68 29% F 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector